Built for what we couldn't find.
Peptides had become one of the most talked-about categories in longevity. The supply chain behind them had become one of the least trustworthy. Origins were vague, documentation was inconsistent, and buyers were asked to trust labels that no one could verify.
Aevivo was founded to build the supply we wanted to buy from: European synthesis, verified purity, and a Certificate of Analysis on record for every peptide. Delivered in a pen format that protects the peptide from production to use.
Suzanna and Tiago met at an art exhibition through a mutual friend. A long conversation about longevity science turned into a shared frustration with how the European peptide market was being supplied: heavy on marketing, light on documentation. Aevivo started as the supplier they wanted to buy from themselves.
Four decades of building businesses across industries taught Suzanna that the quality of life you lead matters more than what you have in the bank. She came into longevity through her network of forward-thinkers, and an IV protocol experience in Colombia two years ago that she still refers to as the moment it clicked. Her frustration with the current peptide market is the misinformation. Her work at Aevivo is to fix it, one educated buyer at a time.
Read Suzanna's story →
Tiago spent eleven years in a career that paid well and taught him a lot, then walked away to build something he actually believed in. A year of searching landed him on longevity, and what pulled him in was less the science and more the state of the supply chain, which he saw as broken in ways that were almost embarrassing. His frustration with the European peptide market is plain: too many companies asking buyers to simply trust them, with no documentation, no traceability, no accountability for what is inside the vial. His work at Aevivo is to build the supplier this market has been waiting for.
Read Tiago's story →Peptides are the start.
We are starting with peptide supply because it is the clearest entry point. The bigger work we are building toward is the full clinical infrastructure clinics need to run peptide protocols defensibly: documented supply, diagnostics, protocol resources, and case support for the practitioners doing the prescribing. Peptides are one tool. The goal is to give clinicians a supply chain and a documentation trail that match the standard their patients deserve.